Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1555 - S-1 plus oxaliplatin combined with radiation (SOX/RT) for preoperative locally advanced rectal carcinoma: final results of a phase II study (JACCRO CC-04: SHOGUN trial)


08 Oct 2016


Poster Display


Hisanaga Horie


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


H. Horie1, S. Matsusaka2, S. Ishihara3, K. Kondo4, K. Uehara5, M. Oguchi6, K. Murofushi6, M. Ueno7, N. Mizunuma8, T. Shimbo9, D. Kato6, J. Okuda10, Y. Hashiguchi11, M. Nakazawa12, E. Sunami3, K. Kawai3, H. Yamashita13, T. Okada14, T. Nakajima15, T. Watanabe3

Author affiliations

  • 1 Surgery, Jichi MedicalUniversity Hospital, 329-0498 - Shimotsuke/JP
  • 2 Gastroenterology, Cancer Institute Hospital of JFCR, Tokyo/JP
  • 3 Department Of Surgical Oncology, University of Tokyo, Tokyo/JP
  • 4 Department Of General & Gastroenterological Surgery, Osaka Medical College, Osaka/JP
  • 5 Department Of Surgical Oncology, Nagoya University, Graduate School of Medicine, Nagoya/JP
  • 6 Radiation Oncology Department, Cancer Institute Hospital of JFCR, Tokyo/JP
  • 7 Department Of Gastroenterological Surgery, Cancer Institute Hospital of JFCR, Tokyo/JP
  • 8 Department Of Gastroenterology, Cancer Institute Hospital of JFCR, Tokyo/JP
  • 9 Department Of Radiology, Osaka Medical College, Osaka/JP
  • 10 Cancer Center, Osaka Medical College Hospital, Osaka/JP
  • 11 Department Of Surgery, Teikyo University, Tokyo/JP
  • 12 Department Of Radiation Oncology, School of Medicine, Jichi Medical University, Tochigi/JP
  • 13 Department Of Radiology, University of Tokyo, Tokyo/JP
  • 14 Department Of Radiology, Nagoya University, Nagoya/JP
  • 15 Gastroenterology, Japan Clinical Cancer Research Organization, Tokyo/JP


Abstract 1555


The study was designed to evaluate the safety and efficacy of adding oxaliplatin to preoperative chemoradiotherpy (CRT) with S-1, an oral fluoropyrimidine in patients with locally advanced rectal carcinoma (LARC). We report here final results of the study.


Patients with histopathologically confirmed LARC (cT3-T4, any N) were eligible. They received oral S-1 (80 mg/m2/day on days 1-5, 8-12, 22-26, and 29-33) and infusional oxaliplatin (60 mg/m2/day on 1, 8, 22, 29) plus radiotherapy (1.8Gy/day, a total dose of 50.4 Gy in 28 fractions), with a chemotherapy gap in the third week of radiotherapy. Primary endpoint of the study was pCR rate. Secondary endpoints were R0 resection rate, down-staging rate, cumulative 3-year local recurrence rate, 3-year disease free survival (DFS) and toxicity.


Forty five patients were enrolled at six centers in Japan. All the patients received CRT, and 44 underwent operation. The pCR rate was 27.3 % (12/44). The R0 resection rate was 95.5 % (42/44). T- down-staging rate was 59.1% (26/44), and N- down-staging rate was 65.9 % (29/44): the combined pathological down-staging rate was 79.5 % (35/44). There were no grade 4 adverse events, and 11.1% of the patients had grade 3 adverse events. No patients suffered from local recurrence. Therefore, cumulative 3-year local recurrence rate was 0%. However, 13 (29.5%) patients suffered from distant metastasis and one patient suffered from a secondary cancer (esophageal cancer). Eight patients had lung metastasis, and 4 had liver metastasis. Three patients died of the metastatic disease. The 3-year DFS of the 44 patients was 67.5% (median follow up 36.3 month), and the 3-year overall survival (OS) was 93.0%. Then the patients were divided into two groups: pCR (12) and non pCR (32) groups. The 3-year DFS of each group was 91.7% and 58.1%, respectively. The 3-year OS was 100% and 90.3%, respectively.


The study showed a high pCR rate with no severe acute toxicity with good follow up results. Therefore, addition of oxaliplatin to preoperative CRT with S-1 in patients with LARC might be feasible and lead to a better local control than standard treatment.

Clinical trial identification

NCT01227239, Oct 18 2010

Legal entity responsible for the study

Toshiaki Watanabe


Taiho Pharmaceutical Co Ltd., Japan


T. Watanabe: Membership on an advisory board: Taiho Pharmaceutical honoraria: Yakult Honsha, Taiho Pharmaceutical All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings